Fatty liver disease is a common but ‘silent’ disease, which means that most people are completely unaware that they have it. As there are no symptoms to alert you to the problem, the fat in the liver keeps building up, and can result in a condition known as non-alcoholic steatohepatitis (NASH).2
Although the exact cause is unknown, we are aware of certain risk factors that make it more likely for some people to develop NASH:3
- Overweight/obese with body fat concentrated around the waist
- Type 2 diabetes
- High cholesterol
- High triglycerides (a type of fat in the blood)
- High blood pressure
Consider taking the first step towards finding out if you have NASH and could be eligible to join an upcoming clinical research study. There is currently an unmet need for a treatment for NASH2, a condition that affects 3-5% of the world’s population1 — that’s approximately 225 to 376 million people.4
The MIRNA study will investigate the potential benefits of two different study drugs (both taken by mouth) for the treatment of NASH with liver fibrosis (initial stage liver scarring).
Could the MIRNA study be an option for you?
It may be an option for you if you are aged 18-75 and have two or more of the risk factors for NASH shown above. There are other requirements for participation in the study. The study doctor will be able to explain these to you.
Why consider a clinical research study?
Clinical research studies are designed to find out more about a particular disease or investigate whether a potential new treatment option could offer greater benefits than the currently available medications or treatments.
What is involved in taking part in the MIRNA study?
The study will compare the effects of the study drugs and/or placebo (inactive) tablets. You would need to take 3 tablets, twice a day with meals, for a period of 50 weeks.
Regular visits to the study clinic will be required for up to 68 weeks for health assessments such as questionnaires, physical examinations, ECG checks, blood and urine samples. To be eligible to join the study, you will also need to have a FibroScan® ultrasound (some study participants may also have an MRI) and agree to a liver biopsy being taken at the start and finish of the study.
Would you like to know more?
Please contact us at (318) 525-3233 for more information about the MIRNA study. Making contact with the study team does not mean that you have to join the study and please know that if you do decide to take part, you can change your mind at any time if you feel the study isn’t right for you.
You can also find out more by visiting www.MIRNAstudy.com
Thank you for your time, we hope to hear from you soon.
- Younossi ZM. J Hepatol 2019; 70: 531-544.
- Chopra S. Patient education: Nonalcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) (Beyond the Basics). UpToDate.com. Available at: https://www.uptodate.com/contents/nonalcoholic-fatty-liver-disease-nafld-including-nonalcoholic-steatohepatitis-nash-beyond-the-basics Accessed March 2020.
- NASH Causes and Risk Factors. American Liver Foundation. Available at: https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/nonalcoholic-steatohepatitis-information-center/nash-causes-risk-factors/ Accessed March 2020.
- One percent of the world’s population. Available at: https://www.quora.com/How-many-people-are-one-percent-of-the-worlds-population Accessed March 2020.